MediWound Ltd
Research MediWound Ltd (MDWD) on Bullrun: market cap USD 167.45M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDWD
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 167.45M
- Financial periodQ1 2026
- RevenueUSD 1.48M
- Net income-USD 2.95M
- Free cash flow-USD 8.57M
- Gross margin21.9%
Valuation Snapshot
latest market cap is USD 167.45M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 16.96M | -USD 23.88M | -USD 21.63M | 19.2% | -2.1 | USD 4.80M | USD 8.15M | USD 43.63M |
| FY2024 | USD 20.22M | -USD 30.22M | -USD 19.90M | 13.0% | -3.07 | USD 9.16M | USD 6.51M | USD 31.15M |
| FY2023 | n/a | n/a | n/a | n/a | -1.33 | USD 11.87M | USD 6.35M | USD 31.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 167.45M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 236.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 192.12M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 93.76M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 78.50M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 64.36M | n/a | n/a | n/a |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MediWound Ltd's market cap?
MediWound Ltd's market capitalization is USD 167.45M.
What does MediWound Ltd do?
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.